Stock AnalizBioNTech SE BNTX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
BioNTech SE (BNTX) is a healthcare company listed in the US with a market value of about $21.5B. In the twelve months to September 30, 2026 it had revenue of $2.7B and net income of -$1.6B, a net margin of -60.9%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is track record (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 42% a year, a 5-year average ROIC of 24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7B | $3.4B | $2.9B | $4.2B | $18.5B | $21.5B | $592M | $122M | $146M | $74M |
| Net income | -$1.6B | -$1.3B | -$691M | $1.0B | $10.1B | $11.7B | $19M | -$201M | -$55M | -$103M |
| Free cash flow | -$524M | $330M | -$82M | $5.7B | $14.1B | $863M | -$98M | -$266M | -$102M | -$92M |
| EPS (diluted) | $-6.49 | $-5.31 | $-2.75 | $4.09 | $40.06 | $46.41 | $0.07 | $-0.80 | $-0.22 | $-0.41 |
| Net margin | -60.9% | -39.6% | -24.2% | 24.4% | 54.5% | 54.2% | 3.1% | -164.9% | -37.6% | -139.1% |
| ROIC | — | -5.8% | -6.7% | 2.7% | 45.9% | 85.7% | -4.0% | -31.9% | -16.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is BioNTech stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does BioNTech pay a dividend?
Not currently.
Is BioNTech a good stock to buy?
We do not give buy or sell advice. BioNTech scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.